

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

-----  
In re Application of: :  
Cornelis Marius TIMMERS et al. :

Serial No.: 10/540,335 :

Int'l Application No.: PCT/EP03/51024 :

Int'l Filing Date: December 16, 2003 :

For: TETRAHYDROQUINOLINE DERIVATIVES :  
AND THEIR USE AS FSH RECEPTOR :  
MODULATORS :

-----  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Docket: 2002.749 US

Group Art Unit:

Examiner:

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First-Class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450

on September 20, 2005

  
Christina Cangelosi

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with the requirements of 37 CFR §1.56, applicants submit the documents attached hereto. Pursuant to the United States Patent and Trademark Office, OG Notice 05 August 2003, applicants have excluded copies of the two (2) U.S. patent documents. All documents are to be made of record in the above-identified case. A listing of said documents on form PTO-1449 is also attached.

The present Information Disclosure Statement is being filed within three months of entrance into the U.S. National stage; therefore, no filing fee is believed to be required. If a filing fee is required, the Commissioner is hereby authorized to charge applicants' deposit account 01-1350 for the full amount of said fee.

A copy of the International Search Report dated June 30, 2004 is enclosed herewith.

This statement is not intended to represent that no better art exists. Applicants reserve the right to contest the applicability of the documents attached hereto as prior art in the event that any information is discovered which demonstrates that said documents do not qualify as prior art.

Consideration of the present Information Disclosure Statement is respectfully requested. The claimed invention is, however, deemed to represent a patentable departure from the teachings of the prior art.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "F. Aaron Dubberley". The signature is fluid and cursive, with the first name "F. Aaron" written in a smaller, more compact script than the last name "Dubberley", which is larger and more prominent.

F. Aaron Dubberley  
Attorney for Applicant(s)  
Reg. No. 41,001

Akzo Nobel Inc.  
Intellectual Property Dept.  
7 Livingstone Avenue  
Dobbs Ferry, NY 10522-3408  
Tel No.: (973) 325-4542

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)  PTO-1449 (modified)				Atty. Docket # 2002.749 US		Serial No. 10/540,335	
				Applicant Cornelis Marius TIMMERS et al.			
				Int'l Filing Date December 16, 2003		Group Art Unit	
U.S. PATENT DOCUMENTS							
Init	Document No.	Issue Date	Name	Class	Subclass	Filing Date	
	6,200,963 B1	3/13/2001	Wrobel et al.	514	150		
	2,686,182	8/10/1954	Hopff et al.	260	287		
FOREIGN PATENT DOCUMENTS							
	Document No.	Publ. Date	Country	Class	Subclass	Translation	
						Y	N
	WO 00/08015	2/17/2000	PCT	C07D	405/00		
	EP 0303 306 B1	2/15/1989	European	A61K	9/70		
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)							
International Search Report, No.: PCT/EP03/51024, 30 June 2004							
Ronald L. Atkins et al., "Substituted Coumarins and Azacoumarins. Synthesis and Fluorescent Properties," J. Org. Chem., Vol. 43, No. 10, pages 1975-1980 (1978)							
Jay V. Johnson et al., "2,4-Diamino-5-benzylpyrimidines and Analogues as Antibacterial Agents. 12.1,2-Dihydroquinolymethyl Analogues with High Activity and Specificity for Bacterial Dihydrofolate Reductase," J. Med. Chem. Vol. 32, pages 1942-1949 (1989)							
James P. Edwards et al., "5-Aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines as Potent, Orally Active, Nonsteroidal Progesterone Receptor Agonists: The Effect of D-Ring Substituents," J. Med. Chem. Vol. 41, pages 303-310 (1998)							
Lawrence G. Hamann et al., "Synthesis and Biological Activity of a Novel Series of Nonsteroidal, Peripherally Selective Androgen Receptor Antagonists Derived from 1,2-Dihydrophyridono[5,6-g]quinolines," J. Med. Chem. Vol. 41, pages 623-639 (1998)							
Maria-Elena Theoclitou et al., "Novel facile synthesis of 2,2,4 substituted 1,2-dihydroquinolines via a modified Skraup reaction," Tetrahedron Letters 43, pages 3907-3910 (2002)							
Jennifer H. Dorrington et al., "Effects of FSH on Gonadal Functions," Recent Progress In Hormone Research, Vo. 35, pages 301-342 (1979)							
"Gonadotropin Therapy: New Trends and Insights," Int J. Fertil, Vol. 33, pages 85-97 (1988)							
Richard M. Sharpe "Intratesticular Control of Steroidogenesis," Clinical Endocrinology, Vol. 33, pages 787-807 (1990)							
Jane H. Morse et al., "Heterogeneity of Proteins in Commercial Preparations of Human Chorionic Gonadotropin (hCG) Demonstrated by Western Blotting," American Journal of Reproductive Immunology And Microbiology, Vol. 17 pages 134-140 (1988)							
Wiebe Olijve et al., "Molecular biology and biochemistry of human recombinant follicle stimulating hormone (Puregon®)," Molecular Human Reproduction, Vol. 2, No. 5, pages 371-382 (1996)							
Daniel Navot et al., "The Use of Follicle-Stimulating Hormone for Controlled Ovarian Hyperstimulation in in Vitro Fertilization," Vol. 4, pages 3-13 (1988)							
"Successful in-vitro fertilisation and embryo transfer after treatment with recombinant human FSH," The Lancet, Vol. 339, pages 1170-1171 (1992)							
EXAMINER				DATE CONSIDERED			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.